A clinical trial conducted at the Hadassah University Medical Center has revealed that BreathID, a new noninvasive device for the detection of hepato-cellular carcinoma, a type of liver cancer, achieved diagnostic results similar to CT Scans and MRIs. BreathID was developed by Exalenz Bioscience Ltd., whose Medical Director is Prof. Yaron Ilan, Director of Hadassah’s Department of Internal Medicine A.
The 36 patients in the trial were first checked by ultrasound; those suspected to have liver cancer underwent a CT Scan or MRI, which revealed that 26 patients had the disease. All the patients were then given breath tests with the BreathID device to determine whether it could achieve similar statistically meaningful results. The device achieved a congruence of 93 percent. Exalenz now plans to begin a larger trial of the device, which will involve 100 patients at five hospitals in Israel, the United States, and Canada.